Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression
Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression
复制标题
前列腺特异性抗原和前列腺特异性抗原衍生物作为良性前列腺增生进展的预测因子
DOI：
10.1007/s11918-007-0003-x
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
K. Slawin
中科院分区：
文献类型：
--
作者：
J. Levitt;K. Slawin
良性前列腺增生（BPH）是老年男性中最常见的泌尿系统疾病，在相当大比例的人群中导致不良临床结局。在过去的二十年中，血清前列腺特异性抗原（PSA）已被确立为前列腺癌的标志物，但最近已被认为是BPH存在和进展的同等重要的标志物。在这段时间里，PSA多种亚型的发现和研究导致了更敏感和特异的方法来区分BPH和前列腺癌。在此，我们回顾PSA及其衍生物的表达，加工和生物化学，并讨论这些亚型的潜力，无论是单独或组合，作为前列腺增生的严重程度和进展的决定因素。
Benign prostatic hyperplasia (BPH) is the most common urologic affliction in aging men, leading to adverse clinical outcomes in a significant proportion of the population. Serum prostate-specific antigen (PSA) has been established as a marker for prostate cancer for the past two decades but more recently has been recognized as an equally important marker of BPH presence and progression. Over this time, the discovery and study of multiple isoforms of PSA has led to even more sensitive and specific methods to differentiate BPH from prostate cancer. Herein we review the expression, processing, and biochemistry of PSA and its derivatives and discuss the potential of these isoforms, both individually and in combination, to serve as determinants of BPH severity and progression.